An oral analgesic in Phase 1 clinical trials designed to treat pain without the adverse effects associated with traditional opioids, such as respiratory depression, sedation, and abuse potential.

A drug discovery platform that identifies highly selective molecules targeting G-protein coupled receptors (GPCRs) to avoid on-target adverse effects.